[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"healthy-adult\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:healthy-adult":30},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,42,0,25,[9,48,77,109,147,172,204,225,249,268,291,311,344,371,403,426,449,478,496,526,551,574,595,615,635],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":18,"sex":19,"minAge":20,"maxAge":21,"enrollmentInfo":22,"targetDuration":4,"studyType":25,"phases":26,"briefSummary":28,"conditions":29,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100644409","finding-immune-nascent-type-1-diabetes-100644409",false,"NCT07663136","Finding Immune Nascent Type 1 Diabetes","Finding Immune Nascent Type 1 Diabetes (FIND T1D)","FIND T1D","Inclusion Criteria:\n\n* Participant must be in Indiana Biobank\n* Participant must be able to provide consent\n* Ages 1-99 including pregnant women\n\nExclusion Criteria:\n\n* Refusal to sign informed consent for home screening is exclusionary for the home screening portion of the study\n* While other medical conditions are allowable prior diabetes diagnosis is exclusionary for home autoantibody screening",true,"ALL","1 Year","99 Years",{"count":23,"type":24},3800,"ESTIMATED","INTERVENTIONAL",[27],"NA","The goal of this clinical trial is to understand how many individuals who previously participated in the Indiana Biobank will return a type 1 diabetes home screening kit based upon different methods of recruitment communication. The main question it aims to answer is:\n\nWhat form of recruitment communication is most effective for completing a type 1diabetes home screening kit?\n\nResearchers will compare two types of recruitment contact: email and mail based communication (low-touch) versus phone contact and follow-up by a research team member (high-touch).\n\nParticipants will be contacted either via email\u002Fmail or by phone and asked if they want to complete a type 1 diabetes home screening kit.",[30,31],"Healthy Adult","Type 1 Diabetes (T1D)",[33,34],"type 1 diabetes home screening kit","type 1 diabetes","NOT_YET_RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-23","ACTUAL",{"date":41,"type":24},"2026-06",{"date":43,"type":24},"2029-06",{"name":45,"class":46},"Indiana University","OTHER",1,{"id":49,"slug":50,"hasResults":12,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":25,"phases":59,"briefSummary":60,"conditions":61,"keywords":62,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":72,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100641658","nicotinamide-riboside-vit-b3-analogue-and-brain-energy-metabolism-100641658","NCT07649161","Nicotinamide Riboside, Vit B3 Analogue, and Brain Energy Metabolism","The Effects of Nicotinamide Riboside Supplementation on Brain NAD+\u002FNADH Ratio and Bioenergetics","Inclusion Criteria:\n\n1. Adults (between 18 and 65 years old)\n2. Without a current psychiatric diagnosis assessed by a structured psychiatric interview at the screening\u002Fconsent visit\n3. Without a history of a psychotic disorder and\u002For mood disorder among parents, siblings, or children\n\nExclusion Criteria:\n\n1. Any current significant medical or neurological illness.\n2. Diagnosis of diabetes mellitus (DM), uncontrolled hypertension (HTN), severe hypotension, coronary artery disease (CAD), metabolic syndrome, glaucoma, liver impairment, decreased renal function, respiratory disorders, and uncontrolled peptic ulcer disease.\n3. Currently taking any other medications, including over-the-counter supplements except oral contraceptives for women and Tylenol as needed for pain or headache.\n4. Currently pregnant or breastfeeding. Females of child-bearing age must be using an effective contraceptive method.\n5. History of substance abuse or dependence.\n6. Contraindication to MR scan (claustrophobia, cardiac pacemakers, metal clips and stents on blood vessels, artificial heart valves, artificial arms, hands, legs, etc., brain stimulator devices, implanted drug pumps, ear implants, eye implants or known metal fragments in eyes, exposure to shrapnel or metal filings, other metallic surgical hardware in vital areas, certain tattoos with metallic ink, certain transdermal patches, metal- containing IUDs)\n7. Medical condition that would prevent blood draws, including current anti-coagulant or anti-aggregant therapy, tendency for abnormal scarring (e.g., keloids).\n8. Difficulty in swallowing capsules.","18 Years","65 Years",{"count":58,"type":24},50,[27],"The goal of this clinical trial is to learn how nicotinamide riboside (NR), a form of vitamin B3, affects brain energy metabolism in healthy adults. Researchers want to find out if taking NR by mouth for 2 weeks can raise the balance of two related brain chemicals called NAD+ and NADH, which play a key role in how cells make and use energy. The main questions are: Does short term NR treatment increase the NAD+ to NADH ratio in the brain, and does it change other brain energy measures that we can see with a special type of MRI scan called phosphorus 31 MR spectroscopy.\n\nAdults between 18 and 65 years old who are generally healthy and do not have a personal or close family history of mood or psychotic disorders may be able to take part. People who join the study will first have a screening visit with a psychiatric interview and safety checks to confirm they are eligible and to review the risks and procedures. Eligible participants will then have a baseline visit that includes a blood draw, vital signs, urine drug and pregnancy tests when needed, and a 7 Tesla MRI\u002FMRS scan focused on brain chemistry and structure.\n\nAfter the baseline visit, participants will take NR capsules by mouth at home, 1500 milligrams in the morning and 1500 milligrams in the early afternoon each day, for about 2 weeks, for a total daily dose of 3000 milligrams. They will be asked to avoid alcohol and other drugs during the study and to complete a short food diary near the end of the dosing period so that researchers can track diet. On the last day of taking NR, participants will return for repeat MRI\u002FMRS scans, blood tests, and vital signs so that researchers can compare brain and blood measures before and after NR treatment.\n\nResearchers will compare each participant's brain NAD+ to NADH ratio and other bioenergetic markers before and after NR to see if NR changes these measures in a consistent way. If NR raises brain NAD+ and improves measures of energy metabolism in healthy adults, this may provide important background information for future studies that test whether NR can help people with psychiatric or neurological disorders linked to mitochondrial dysfunction and oxidative stress. There is no expected direct health benefit for participants, but their involvement may help improve understanding of how NR affects human brain metabolism.",[30],[63,64,65,66,67,68],"Nicotinamide riboside supplementation","Vitamin B3 analogs","Nicotinamide adenine dinucleotide metabolism","Brain energy metabolism","Phosphorus 31 magnetic resonance spectroscopy","Brain bioenergetics imaging","RECRUITING","2026-06-15",{"date":36,"type":39},{"date":41,"type":24},{"date":74,"type":24},"2028-01",{"name":76,"class":46},"Massachusetts General Hospital",{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":82,"eligibilityCriteria":83,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":84,"enrollmentInfo":85,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":88,"conditions":89,"keywords":92,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":107,"locationsCount":4},"100641671","ultrasound-muscle-biomarkers-as-predictors-of-isometric-quadriceps-muscle-strength-and-handgrip-in-healthy-adults-an-observational-study-100641671","NCT07647393","Ultrasound Muscle Biomarkers as Predictors of Isometric Quadriceps Muscle Strength and Handgrip in Healthy Adults: an Observational Study","MUSCLE-US","Inclusion Criteria:\n\n* Healthy adults aged 18-89 years.\n* Resident in Spain for at least 5 years.\n* Living independently in the community and able to complete all study assessments.\n* Able to understand and follow verbal instructions in Spanish.\n* Able and willing to provide written informed consent prior to study participation.\n\nExclusion Criteria:\n\n* Neurological, musculoskeletal, or systemic disorders affecting muscle strength or mobility.\n* Recent surgery or acute injury affecting the upper or lower limbs.\n* Recent use of medications affecting the musculoskeletal system (e.g., systemic corticosteroids for \\>1 week during the previous 6 months or muscle relaxants during the previous week).\n* Cognitive or psychiatric conditions limiting participation.\n* Pregnancy.\n* Recent postpartum period (≤3 months after delivery).\n* Presence of clinically relevant pain, fatigue, physical deconditioning, or functional limitations that may interfere with study procedures or measurement validity.\n* Acute illness at the time of assessment.\n* Uncontrolled hypertension (≥140\u002F90 mmHg).\n* Resting peripheral oxygen saturation ≤90%.\n* Moderate-to-severe pain (Numeric Rating Scale ≥4\u002F10).\n* Any medical condition considered by the investigator to contraindicate study participation.","89 Years",{"count":86,"type":24},300,"OBSERVATIONAL","This observational study aims to determine whether ultrasound-derived muscle biomarkers can predict isometric quadriceps muscle strength and handgrip in healthy adults aged 18-89 years.\n\nThe main questions it aims to answer are:\n\n* Which ultrasound muscle characteristics are associated with isometric quadriceps muscle strength and handgrip?\n* Can ultrasound-derived biomarkers be used to develop predictive models of muscle strength in healthy adults?\n\nParticipants will undergo:\n\n* Ultrasound assessment of the quadriceps and forearm flexor muscles;\n* Measurement of isometric quadriceps muscle strength and handgrip using standardized dynamometry protocols;\n* Assessment of functional capacity, mobility and balance;\n* Completion of questionnaires related to health status, physical activity, nutrition, fatigue and health-related quality of life.\n\nThe study will also assess the reliability of ultrasound measurements and explore the relationship between ultrasound variables, muscle strength, physical function and health-related factors.",[30,90,91],"Muscle Strength","Skeletal Muscle Ultrasound",[93,94,95,96,97,98,99,100,101],"Muscle ultrasound","Skeletal muscle ultrasonography","Muscle biomarkers","Isometric quadriceps muscle strength","Handgrip","Muscle thickness","Echo intensity","Muscle quality","Predictive models","2026-06-12",{"date":104,"type":39},"2026-06-16",{"date":41,"type":24},{"date":43,"type":24},{"name":108,"class":46},"University of Alcala",{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":18,"sex":19,"minAge":116,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":25,"phases":120,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":139,"lastUpdatePostDateStruct":140,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":47},"100633481","phase-2-improving-vaccine-protection-for-adults-100633481","NCT07527247","Improving Vaccine Protection for Adults","Using AS01 Adjuvant to Improve Immune Response in Older Adults Through Trained Immunity","Inclusion Criteria:\n\n* Adults aged 21 to 59 years of age at time of screening.\n* BMI 18.5 - 27.5 kg \u002F m2 (BMI values for Asian population according to MOH guideline NIH Consensus Conference).\n* Satisfactory baseline medical assessment as assessed by physical examination and a stable health status. For subjects with underlying comorbidities, the conditions must be deemed stable by the investigators, and they must not have any hospitalisation relating to these conditions in the last 6 months.\n* Voluntarily participate, understand and sign an informed consent form approved by the Ethical Review Board.\n* Subjects who are willing to comply with the requirements of the study protocol and scheduled visits. These requirements include completion of the subject diary, return for follow-up visits. Subjects should also be willing to make themselves available for the duration of the study, with access to a consistent means of contact.\n* Accessible vein at the forearm for blood taking.\n* Female subjects of non-childbearing potential due to surgical sterilisation (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause. Post-menopausal subjects must have had at least 12 months of natural (spontaneous) amenorrhoea.\n\nExclusion Criteria:\n\n* Previous vaccination against yellow fever, dengue either with a registered product or from participation in a previous vaccine study.\n* Previously received AS01-adjuvanted vaccines (e.g. Recombinant zoster vaccine, RTS,S\u002FAS01, RSVPre-F3-AS01), either with a registered product or from participation in a previous vaccine study.\n* Planned administration of a AS01-adjuvanted vaccine or yellow fever vaccine other than the study vaccine during the study.\n* Subjects who have been unwell in the last 7 days prior to screening.\n* History of documented yellow fever and \u002F or dengue infection.\n* Dengue seropositivity upon screening.\n* History of smoking within the last 1 year.\n* Planned travel to yellow fever endemic countries during the study.\n* Known allergy to AS01 and YF17D vaccine or their components (e.g. egg products).\n* Diagnosis of diabetes HBA1c \\> 6.5 according to American Diabetes Association criteria62.\n* Any medical condition that in the judgment of the investigator will make intramuscular injection unsafe (e.g. thrombocytopenia with platelet count \\\u003C 50x10\\^9\u002FL, coagulopathy, anti-coagulant therapy).\n* Risk factor for live-attenuated vaccines, including any confirmed or suspected primary or acquired immunodeficiency based on history and physical examination:\n\n  * History of thymus gland disease\n  * Haematologic neoplasms including leukaemia, lymphoma, myelodysplastic syndromes\n  * Diagnosed with cancer or treatment for cancer (except for localised basal cell carcinoma) within 3 years prior to screening\n  * Post-transplant: solid organ and haematopoietic stem cell transplant\n  * Immunocompromised due to primary or acquired (including HIV\u002FAIDS) immunodeficiency\n  * Other significantly immunocompromising conditions\n* Administration of anti-inflammatory drugs for the past 7 days (e.g. NSAIDs, Paracetamol, aspirin).\n* Use of metformin for the last 1 month.\n* Use of corticosteroids within the last 6 months prior to the first vaccine dose (defined as prednisolone \\> 10 mg \u002F day or equivalent for \\> 2 weeks, or prednisolone \\> 40mg \u002F day or \\> 1 week). Inhaled and topical steroids are allowed.\n* Received biologics (such as anti-TNF inhibitors, IL-1 inhibitors, co-stimulation blockers, B-cell depleting therapy) for the last 12 months.\n* Any condition (e.g. extensive psoriasis, chronic pain syndrome, severe hearing loss, cognitive impairment, dialysis, autoimmune disorders) that in the opinion of the investigator, would complicate or compromise the study or wellbeing of the subject, or prevent completion of the study.\n* Evidence of substance abuse, or previous substance abuse.\n* Clinically significant anaemia (Hb \\\u003C 10 g\u002FdL).\n* Blood donation exceeding \\> 450 ml in the past 3 months.\n* Participation in a study involving administration of an investigational or non-investigational compound within the past four months or planned participation during the duration of this study.\n* Administration of any licensed vaccine within 30 days before the first study vaccine dose or planned to receive such products within 30 days after the study vaccination.\n* Received immunoglobulin or any blood products within the 90 days preceding the first dose of study vaccine or planned to receive such products during the study period.","21 Years","59 Years",{"count":119,"type":24},40,[121],"PHASE2","As people grow older, their immune system - the body's natural defence against diseases - becomes weaker, making them more vulnerable to infections and less responsive to vaccines. This was clearly seen during the COVID-19 pandemic, where older adults were more likely to develop severe illness. Researchers have made an interesting discovery about AS01, an ingredient already used in successful vaccines like the shingles vaccine. They found clues that AS01 might work like a general fitness trainer for the immune system, potentially making it stronger and better at fighting off various types of infections, not just specific ones. To confirm this possibility, we are conducting this research study with adults aged 21-59 to test whether AS01 by itself can boost and train the immune system, how long this boost lasts, and if it actually helps you fight off other infections more effectively.",[124,30],"Immune System Responses and Trained Immunity After AS01 Administration",[126,127,128,129,130,131,132,133,134,135,136,137,138],"AS01","AS01 adjuvant","Immune durability","Immune system","Immune response modulation","Recombinant zoster vaccine adjuvant","Vaccine","Randomized","Placebo-controlled","Blinded","Healthy volunteers","Protective effects","Yellow Fever Vaccine","2026-06-11",{"date":70,"type":39},{"date":142,"type":39},"2025-11-06",{"date":144,"type":24},"2029-02-28",{"name":146,"class":46},"Singapore General Hospital",{"id":148,"slug":149,"hasResults":12,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":56,"enrollmentInfo":154,"targetDuration":4,"studyType":25,"phases":156,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":4},"100624057","safety-and-effects-of-high-intensity-blood-flow-restriction-training-in-the-rotator-cuff-100624057","NCT07404683","Safety and Effects of High-Intensity Blood Flow Restriction Training in the Rotator Cuff","Safety, Utility and Effects After 8 Weeks of High-intensity Strength Training With Blood Flow Restriction in the Rotator Cuff","Inclusion Criteria:\n\n* Healthy, untrained adults\n* Age between 18 and 65\n\nExclusion Criteria:\n\n* Current participation in an upper limb strength training program\n* Presence of comorbidities that increase cardiovascular risk (uncontrolled ischemic heart disease, uncontrolled hypertension, diabetes, etc.)\n* Patients with more than one thromboembolism risk factor (obesity, history of thrombosis, prolonged immobilization, recent surgery, use of contraceptives, etc.)\n* Current diagnosis of any pathology affecting the cervical spine, shoulder, and\u002For thoracic spine\n* History of surgery in the last year\n* Use of ergogenic aids or medications that affect muscle metabolism (anabolic steroids, testosterone, creatine, protein supplements, corticosteroids, chronic use of nonsteroidal anti-inflammatory drugs, etc.)",{"count":155,"type":24},60,[27],"This study aims to analyze the effects of an 8-week strength training program combining different exercise intensities and blood flow restriction (BFR) conditions on safety, tolerability, muscle adaptations, and physical performance variables. Three training modalities will be compared: 1) high-intensity exercise with BFR therapy; 2) low-intensity exercise with BFR therapy; and 3) high-intensity exercise without BFR therapy. All groups will perform the same exercise modality, differing only in intensity and the application of BFR.\n\nParticipants will be randomly assigned to one of the three groups and will undergo a 8-week intervention. The variables of interest will be assessed in each group for subsequent analysis and comparison.",[30],[160,161,162,163],"blood flow restriction","exercise","high-intensity","rotator cuff","2026-06-08",{"date":139,"type":39},{"date":167,"type":24},"2026-09",{"date":169,"type":24},"2028-06",{"name":171,"class":46},"University of Valencia",{"id":173,"slug":174,"hasResults":12,"nctId":175,"briefTitle":176,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":18,"sex":19,"minAge":179,"maxAge":180,"enrollmentInfo":181,"targetDuration":4,"studyType":25,"phases":183,"briefSummary":185,"conditions":186,"keywords":189,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":47},"100642604","early-phase-1-evaluation-of-fmodag-009-pet-imaging-in-synucleinopathies-100642604","NCT07640555","Evaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies","MODAG-009-P1-0","Inclusion Criteria:\n\n* Healthy Controls inclusion criteria:\n\n  1. Enrolled in the PPMI 002 Clinical study as a healthy control participant\n  2. Any gender aged 50 to 75 years of age\n  3. Negative CSF α-synuclein seed amplification assay (SAA)\n  4. Previously acquired (since inclusion in PPMI) brain MRI without evidence of significant neurological pathology.\n  5. Movement Disorders Society- Unified Parkinson's Disease Rating Scale Part III (MDS-UPDRS III) score of \\\u003C6 at the last PPMI annual visit which is within the past 18 months.\n  6. Cognitively intact with Montreal Cognitive Assessment (MoCA) greater than or equal to 26 at the last PPMI annual visit which was within the past 18 months.\n* Parkinson's Disease and Prodromal PD inclusion criteria:\n\n  1. Enrolled in the PPMI 002 Clinical study as a Parkinson's Disease (PD) or Prodromal participant\n  2. Any gender aged 50 to 80 years of age\n  3. Positive CSF SAA\n  4. A current or previously acquired brain MRI (since the onset of motor symptoms for PD or since enrolled in PPMI for the prodromal PD) without evidence of significant neurological pathology other than changes expected for PD.\n  5. Montreal Cognitive Assessment (MoCA) greater than or equal to 24 at the last PPMI annual visit which was within the past 18 months.\n* Multiple System Atrophy (MSA) inclusion criteria:\n\n  1. Any gender aged 50 to 75 years of age\n  2. Clinically established MSA or Clinically Probable MSA according to the Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (Wenning et al., 2022)\n  3. Positive CSF SAA\n  4. A current or previously acquired brain MRI (since the onset of motor symptoms attributed to MSA) without evidence of significant neurological pathology other than the pathology expected for MSA.\n  5. Evidence of nigrostriatal degeneration on DaTscan obtained at screening or on previously acquired imaging since the onset of the motor symptoms attributed to MSA.\n\nExclusion Criteria:\n\n* All Cohorts:\n\n  1. Clinical evidence of other neurodegenerative diseases, such as Alzheimer's disease\n  2. Any other medical or psychiatric condition or lab abnormality, which in the opinion of the investigator might preclude participation.\n  3. Received any of the following drugs: dopamine receptor blockers (neuroleptics), metoclopramide, lithium and reserpine, within 6 months of Baseline Visit.\n  4. Any other reason that in the opinion of the investigator, including abnormal labs, that could interfere with the safety with radiotracer injection, would render the participant unsuitable for the study enrollment.\n  5. Participation in an investigational drug trial targeting α-synuclein within the past 6 months prior to enrollment.\n  6. Currently being treated with and unable to safely hold antiplatelets (other than low dose aspirin up to 100mg\u002Fday) or anticoagulants prior to the procedure that might preclude safe attempt of Lumbar puncture, if applicable.\n  7. Condition that precludes the safe performance of routine lumbar puncture, if applicable, such as prohibitive lumbar spinal disease, bleeding diathesis, or clinically significant and uncorrected coagulopathy or thrombocytopenia.\n  8. Conditions or medications that preclude safe performance of imaging procedures (MRI or DaTscan), including but not limited to severe claustrophobia, MRI-incompatible metal implants, or known hypersensitivity to imaging agents.\n  9. Known hypersensitivity to DaTscan or iodine-containing compounds used as premedication for DaTscan. Participants with iodine sensitivity may still complete the imaging without iodine premedication at the investigator's discretion.\n  10. Use of medications known to interfere with DaTscan imaging (e.g., bupropion, amphetamines, methylphenidate, modafinil, alpha-methyldopa), unless the participant is willing and medically able to hold the medication for at least 5 half-lives or specified duration per investigators judgement prior to imaging.","50 Years","80 Years",{"count":182,"type":24},13,[184],"EARLY_PHASE1","This is a single-center, open-label clinical study designed to evaluate the imaging characteristics and safety of \\[¹⁸F\\]MODAG-009 in participants with Parkinson's disease (PD), Multiple system atrophy (MSA), and Healthy controls (HC). Approximately 13 participants will be enrolled in this study. Each participant will receive a single intravenous injection of \\[¹⁸F\\]MODAG-009, followed by PET imaging using the investigational United Imaging NeuroEXPLORER (NX) camera.",[187,30,188],"Multiple System Atrophy (MSA)","Parkinson Disease",[190,191,192,193,194],"MODAG","MODAG GmbH","MODAG-009","PET Tracer","Synuclein","2026-06-06",{"date":197,"type":39},"2026-06-10",{"date":199,"type":39},"2026-05-13",{"date":201,"type":24},"2027-05",{"name":191,"class":203},"INDUSTRY",{"id":205,"slug":206,"hasResults":12,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":18,"sex":19,"minAge":211,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":25,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":222,"leadSponsor":223,"locationsCount":47},"100643815","phase-1-a-study-to-exploratively-evaluate-the-safety-tolerability-and-pharmacokinetics-of-da-5223-compared-with-da-5223-r-in-healthy-adult-subjects-100643815","NCT07633691","A Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects","An Open-label, Randomized, Single-dose, Two-Cohort, Two-Period, Crossover Study to Exploratively Evaluate the Safety, Tolerability and Pharmacokinetics of DA-5223 Compared With DA-5223-R in Healthy Adult Subjects","Inclusion Criteria:\n\n* Adult male or female, 19 years to 55 years\n* Male weighing 50 kg or more, female weighing 45 kg or more with a body mass index (BMI) of 18.0 kg\u002Fm2 to 30.0 kg\u002Fm2\n* The subjects signed and dated informed consent form after hearing a detailed explanation of the study, fully understanding and determined voluntarily to participate\n\nExclusion Criteria:\n\n* The subjects with acute illness\n* The subjects with a history of gastrointestinal disease or surgery that may affect the absorption of Investigational Product\n* The subjects hypersensitive to any of the Investigational Product components or other drug components\n* The subjects who have continuously consumed excessive smoking or alcohol within 1 months of screening, or who cannot stop smoking, caffeine, or alcohol intake during hospitalization\n* The subjects who are pregnant or lactating","19 Years","55 Years",{"count":214,"type":24},12,[216],"PHASE1","This study will exploratively evaluate the safety, tolerability and pharmacokinetics of DA-5223 compared with DA-5223-R in healthy adult subjects",[30],"2026-06-04",{"date":164,"type":39},{"date":41,"type":24},{"date":41,"type":24},{"name":224,"class":203},"Dong-A ST Co., Ltd.",{"id":226,"slug":227,"hasResults":12,"nctId":228,"briefTitle":229,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":231,"enrollmentInfo":232,"targetDuration":4,"studyType":25,"phases":234,"briefSummary":235,"conditions":236,"keywords":237,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":248,"locationsCount":47},"100640482","early-phase-1-evaluation-of-the-pharmacokinetics-biodistribution-and-radiation-dosimetry-of-18fmodag-009-positron-emission-tomography-pet-radiotracers-in-adult-healthy-volunteers-100640482","NCT07617688","Evaluation of the Pharmacokinetics, Biodistribution and Radiation Dosimetry of [18F]MODAG-009 Positron Emission Tomography (PET) Radiotracers in Adult Healthy Volunteers","Inclusion Criteria:\n\n* Male or Female,\n* aged 18 to 60 years old\n* in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening.\n* Ability to comply with the study procedures.\n* Able to understand and sign written informed consent from the participant.\n* Male and Females must meet additional criteria specified below, as applicable\n* a. Females must be of non-childbearing potential or using a highly effective method of birth control 14 days prior to until at least 24 hours after injection of \\[18F\\]MODAG-009. (i. Non-childbearing potential is defined as a female that must be either postmenopausal (no menses for at least 12 months prior to PET scan) or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). ii. Highly effective method of birth control is defined as practicing at least one of the following: A birth control method that results in a less than 1% per year failure rate when used consistently and correctly, such as oral contraceptives for at least 3 months prior to injection, an intrauterine device (IUD) for at least 2 months prior to injection, or barrier methods, e.g., diaphragm or combination condom and spermicide. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) is not acceptable.)\n* b. Females of childbearing potential must not be pregnant, breastfeeding or lactating, or planning pregnancy during the duration of the study.\n* c. Males with female partners of childbearing potential must use adequate contraceptive methods and refrain from sperm donation for 90 days after injection of \\[18F\\]MODAG-009\n\nExclusion Criteria:\n\n* Use of any prescription drugs, herbal supplements, within four (4) weeks prior to initial dosing, and\u002For over-the-counter (OTC) medication, dietary supplements (vitamins included) within two (2) weeks prior to initial dosing. If needed (i.e. an incidental and limited need), acetaminophen is acceptable, but must be documented as a concomitant medication \u002F significant non-drug therapy. Participation in any clinical interventional studies within four (4) weeks prior to initial dosing or 5 half-lives of the investigational agent if known and longer than four (4) weeks.\n* Participants with a history of exposure to any radiation \\>50 mSv\u002Fyear (e.g., occupational or radiation therapy) over the past year. Donation or loss of 400 ml or more of blood within eight (8) weeks prior to initial dosing, or longer if required by local regulation.\n* Have a history or presence of any significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, or neurological disorders which, in the opinion of the investigator, are capable of altering the absorption, metabolism, or elimination of drugs or posing a health risk to participate in the study.\n* Have clinically significant findings on laboratory evaluations.\n* Have clinically significant findings on ECG evaluation.\n* History of immunodeficiency diseases, including a positive HIV test result.\n* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C antibody test result.\n* History of drug or alcohol abuse within the 12 months prior to screening, or evidence of such abuse as indicated by the laboratory assays conducted during the screening.\n* History of tobacco product use within 3 months prior to screening, to be verified by urine cotinine screening.\n* Positive pregnancy test result, if female.\n* Women who are lactating and breastfeeding.","60 Years",{"count":233,"type":24},6,[184],"This is an open-label, single-center, phase 1 study to further characterize \\[18F\\]MODAG-009 in Healthy Volunteers (HV). Approximately 6 participants will be enrolled in this study. Each participant will receive a single dose of \\[18F\\]MODAG-009 radiotracer and undergo whole body PET imaging covering up to 10 bed positions to capture the whole body from skull vertex to mid-thigh.",[30],[190,191,194,238,239,240,241,242,192],"MSA","Multiple System Atrophy","Parkinson","Parkinson´s disease","PET tracer","2026-06-02",{"date":219,"type":39},{"date":246,"type":39},"2026-05-27",{"date":201,"type":24},{"name":191,"class":203},{"id":250,"slug":251,"hasResults":12,"nctId":252,"briefTitle":253,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":18,"sex":19,"minAge":257,"maxAge":179,"enrollmentInfo":258,"targetDuration":4,"studyType":25,"phases":259,"briefSummary":260,"conditions":261,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":266,"locationsCount":47},"100640661","modulation-of-appetite-signaling-through-enterohormone-stimulation-by-dnf-10-100640661","NCT07621393","Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10","Modulation of Appetite Signaling Through Enterohormone Stimulation by DNF-10: Pilot Proof-of-concept, Crossover, Exploratory, Randomized, Double-blind, Placebo-controlled Study","DNF10-APET","Inclusion Criteria:\n\n* Healthy men and women aged 20 to 50 years.\n* Body Mass Index (BMI) of 18.5-24.9 kg\u002Fm² or 25.0-29.9 kg\u002Fm².\n* Stable use of permitted medications and\u002For dietary supplements during the study.\n* Individuals willing to maintain their usual dietary and physical activity habits throughout the study.\n* Subjects capable of understanding and complying with the study procedures.\n* Subjects who have signed the informed consent form.\n* Female participants must meet one of the following conditions:\n\n  1. Women with no potential for pregnancy, defined as women who have undergone surgical sterilization or who are postmenopausal.\n  2. Women of childbearing potential who use a highly effective contraceptive method (hormonal contraception, intrauterine device, condoms, male partner sterilization \\[vasectomy\\], or complete sexual abstinence) while participating in the study.\n\nExclusion Criteria:\n\n* Individuals with known eating behavior disorders (verified using the Spanish version of the Adult Eating Behavior Questionnaire, AEBQ).\n* Subjects with a body weight gain or loss ≥10% within the previous 3 months.\n* Treatment with medications or dietary supplements for weight loss, satiety, or glucose control.\n* Individuals consuming protein powders or dietary supplements related to the objectives of the study.\n* Participants receiving active treatment with GLP-1 receptor agonists or similar agents.\n* Participants taking medications or dietary supplements that, in the investigator's opinion, may interfere with the study objectives (e.g., affecting appetite), pose a safety risk, or confound the interpretation of the study results.\n* Depression or anxiety disorders that affect appetite.\n* High coffee consumption (more than 4 cups per day).\n* Smokers (more than 5 cigarettes per week), smoking during study assessment days, and\u002For drug abuse.\n* History of bariatric surgery within the last 3 years.\n* Low iron levels requiring treatment.\n* Individuals with renal or endocrine diseases (including diabetes).\n* Untreated or unstable hyperthyroidism, suicidal ideation, bipolar disorder, or evidence of any untreated or unstable neurological disorder.\n* Conditions or diseases that, in the investigator's judgment, may be worsened by participation in the study or may jeopardize the conduct of the study.\n* Presence of infectious diseases at the time of study inclusion (participants may be included 1 month after resolution of the illness).\n* Severely immunocompromised participants (transplant recipients, individuals treated with anti-rejection medications or steroids within the previous 30 days, or those who have received chemotherapy or radiotherapy within the last year).\n* Presence of active malignancy or any concomitant end-stage organ disease within the last 12 months that, in the investigator's judgment, contraindicates participation in the study.\n* Hypersensitivity, allergy, or intolerance to any of the components of the study product or standardized study menus (e.g., cow's milk protein allergy \\[CMPA\\], celiac disease, or non-celiac gluten intolerance).\n* Current participation or participation in another clinical trial within the previous three months.\n* Pregnant or breastfeeding women, women seeking pregnancy, or women of childbearing potential who are unwilling to use an effective contraceptive method.","20 Years",{"count":58,"type":24},[27],"This is a pilot, proof-of-concept, exploratory, randomized, double-blind, placebo-controlled crossover study. The study will be conducted in 50 healthy volunteers with a body mass index (BMI) between 18.5 and 29.9 kg\u002Fm². The objective is to comprehensively evaluate the potential of DNF-10 to modulate appetite through the regulation of enteroendocrine hormones and to determine its relevance in human physiology.",[30],{"date":219,"type":39},{"date":264,"type":39},"2026-05-12",{"date":167,"type":24},{"name":267,"class":203},"Fytexia",{"id":269,"slug":270,"hasResults":12,"nctId":271,"briefTitle":272,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":212,"enrollmentInfo":275,"targetDuration":4,"studyType":25,"phases":277,"briefSummary":278,"conditions":279,"keywords":281,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":285,"completionDateStruct":287,"leadSponsor":289,"locationsCount":4},"100640012","phase-1-a-phase-i-single-and-multiple-dose-study-to-evaluate-the-safety-pharmacokinetics-and-pharmacodynamics-of-hs-10522-in-healthy-chinese-participants-and-chinese-participants-with-mild-hypertension-100640012","NCT07609875","A Phase I Single and Multiple Dose Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of HS-10522 in Healthy Chinese Participants and Chinese Participants With Mild Hypertension","A Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Oral Doses of HS-10522 Tablets in Healthy Chinese Participants and Chinese Participants With Mild Hypertension","Inclusion Criteria:\n\n\\-\n\nFor all participants:\n\n1. Able to understand the procedures and methods of the study, willing to strictly adhere to the clinical trial protocol to complete the study, and voluntarily sign the Informed Consent Form (ICF).\n2. Male or female participants aged 18 to 55 years (inclusive) at the time of signing ICF.\n3. At screening, body weight ≥ 50 kg for males and ≥ 45 kg for females, with a body mass index (BMI) between 19.0 and 28.0 kg\u002Fm² (inclusive).\n\nExclusion Criteria:\n\n1. Abnormal vital signs, physical examination findings, or laboratory test results at screening that are deemed clinically significant by the investigator.\n2. Presence of orthostatic hypotension or orthostatic tachycardia at screening.\n3. Clinically significant abnormal findings on the 12-lead ECG at screening, as judged by the investigator.\n4. Use of any medication within 2 weeks or 5 half-lives (whichever is longer) prior to screening, or anticipation of needing such medication during the trial.\n5. Known secondary causes of hypertension, or diseases that may affect adrenal function (e.g., renal artery stenosis, poorly controlled or untreated hyperthyroidism, poorly controlled or untreated hypothyroidism, hyperparathyroidism, pheochromocytoma, Cushing's syndrome).\n6. Participation in any other clinical trial of a drug or medical device within 12 weeks prior to screening, with receipt of at least one dose (including placebo), or currently within 5 half-lives of the last dose of the investigational product (whichever is longer).\n7. Participants who, in the opinion of the investigator, are likely to be non-compliant or are unsuitable for participation in this trial for any other reason.",{"count":276,"type":24},88,[216],"The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending single and multiple oral doses of HS-10522 in healthy Chinese participants and Chinese participants with mild hypertension.",[30,280],"Hypertension",[282],"hypertension","2026-05-19",{"date":246,"type":39},{"date":286,"type":24},"2026-06-01",{"date":288,"type":24},"2027-02-03",{"name":290,"class":203},"Jiangsu Hansoh Pharmaceutical Co., Ltd.",{"id":292,"slug":293,"hasResults":12,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":212,"enrollmentInfo":298,"targetDuration":4,"studyType":25,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":303,"lastUpdatePostDateStruct":304,"startDateStruct":306,"completionDateStruct":307,"leadSponsor":309,"locationsCount":47},"100637255","phase-1-bioequivalence-study-of-ferric-carboxymaltose-injection-in-healthy-chinese-participants-under-fasting-conditions-100637255","NCT07606105","Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions","A Randomized, Open-label, Two-treatment, Two-period, Two-cross-over Bioequivalence Study of Ferric Carboxymaltose Injection in Healthy Chinese Participants Under Fasting Conditions","Inclusion Criteria:\n\n1. Participants must fully understand the purpose, nature, procedures, and potential adverse reactions of the study. They must voluntarily agree to participate in the trial, comply with all study requirements, and provide written informed consent before the initiation of any study procedures.\n2. Healthy male or female participants aged 18 to 55 years (inclusive).\n3. Participants must have a body weight of ≥ 50.0 kg; Body Mass Index(BMI) must range from 19.0 to 26.0 kg\u002Fm² (inclusive).\n4. Participants have been using effective contraception for 14 days prior to screening. Participants must agree to use highly effective contraceptive measures from screening until 3 months after the last administration. They must have no plans for pregnancy, sperm donation, or egg donation during this period.\n\nExclusion Criteria:\n\n1. Participants with allergic conditions, such as a known history of hypersensitivity to two or more medications; known allergies to iron, maltose, or its analogues\u002F metabolites; or a history\u002Fpresence of severe asthma, eczema, or other atopic allergic disorders.\n2. History\u002Fpresence of iron storage diseases (e.g., hemochromatosis), iron utilization disorders (e.g., iron-refractory iron deficiency anemia), hemoglobinopathies (e.g., thalassemia), hemolytic anemia, symptomatic anemia requiring red blood cell infusion, or undergoing hemodialysis.\n3. History of iron deficiency or anemia within 6 months prior to screening.\n4. History of clinically significant chronic or severe conditions affecting the respiratory, cardiovascular, gastrointestinal, renal, hematological, lymphatic, endocrine, immune, psychiatric, or nervous systems; past or current diagnosis of porphyria cutanea tarda; or other conditions deemed by the investigator to be unsuitable for participation.\n5. Acute conditions (e.g., acute infection, acute gastrointestinal disorders such as nausea, vomiting, diarrhea, or constipation, etc.) within 2 weeks prior to the first dose.\n6. Participants with clinically significant abnormalities in vital signs, physical examination, laboratory tests (e.g., hematology, urinalysis, blood chemistry, coagulation function tests, iron metabolism assessments), infectious disease testing, or 12-lead Electrocardiogram (ECG), as determined by the investigator (special requirement: calcium and phosphorus values in blood chemistry tests are in the abnormal range). Hepatic enzyme levels exceeding 1.5 times the upper limit of normal (ULN) during screening. Serious arrhythmias shown in ECG at screening, such as recurrent or symptomatic ventricular tachycardia, atrial fibrillation accompanied by rapid ventricular response, or supraventricular tachycardia.\n7. History of hypersensitivity or intolerance to intravenous iron administration.\n8. Receiving parenteral iron treatment within 6 months prior to screening, erythropoiesis-stimulating agent (ESA) therapy and\u002For blood transfusion within 4 weeks prior to screening.\n9. Use of any medication that may affect iron absorption iron absorption within 28 days prior to dosing, such as antacids (e.g., omeprazole), tetracycline antibiotics, calcium supplements, or lipid-lowering agents (e.g., cholestyramine).\n10. Use of any medications (prescription, over-the-counter, herbal remedies, or dietary supplements) and healthcare products within 2 weeks prior to screening.\n11. History of smoking an average of more than 5 cigarettes per day within 3 months prior to screening or unwillingness to abstain from smoking from 48 hours prior to dosing until the completion of blood sampling in each treatment period.\n12. Participants who have undergone surgeries within 6 months prior to screening that might affect drug absorption, distribution, metabolism and excretion, or planning to undergo surgeries during the study.\n13. Participants who have enrolled in other clinical trials and received investigational products or devices within 3 months prior to screening.\n14. Blood donation or significant blood loss due to other reasons within 3 months prior to screening (\\> 400 mL, excluding menstrual blood loss in female participants), or donated platelets in an amount equal to or exceeding 2 therapeutic doses (1 therapeutic dose = 12 units of platelets) within 1 month prior to screening, or plan to donate blood during the study.\n15. Participants with drug abuse history (including the use of various anesthetic and psychotropic drugs for non-medical purposes) within 1 year prior to screening or have a positive drug abuse screening result.\n16. Participants with history of alcohol abuse within 1 year prior to screening, defined as average daily alcohol consume over 2 units (1 unit = 360 mL beer, 45 mL spirits with 40% alcohol, or 150 mL wine), or are unwilling to abstain from alcohol or alcohol-containing products from 48 hours prior to dosing until the completion of blood sampling in each treatment period, or have positive breath alcohol test result.\n17. Participants who have special diet: xanthine-rich foods (e.g., coffee, chocolate, tea or cocoa beverages), iron-rich foods including animal organs, animal blood, spinach, as well as calcium\u002Fphosphorus-rich seafood, shellfish, crab, and nuts such as peanuts and sunflower seeds, dragon fruit, mango, grapefruit or grapefruit-containing products, or taking strenuous exercise, or other factors affecting drug absorption, distribution, metabolism, and excretion, within 48 hours before receiving the first dose of investigational product.\n18. Participants who received a live vaccine within 14 days prior to screening, or plan to receive vaccination during the study.\n19. Inability to tolerate venipuncture or history of fear of needles or hemophobia.\n20. Participants with special dietary requirements, and participants who cannot accept the study standardized diet.\n21. Any other condition deemed by the investigator to be unsuitable for enrollment.\n\n    In addition to the aforementioned requirements, females who meet the following conditions should also be excluded:\n22. Use of oral contraceptives within 30 days prior to screening.\n23. Use of long-acting estrogen or progestin injections (progestin-based intrauterine devices), or implants within 6 months prior to screening.\n24. Pregnancy, breastfeeding, or positive pregnancy test at screening.",{"count":299,"type":24},70,[216],"The goal of this clinical trial is to compare the pharmacokinetic profile of the developed drug product and reference product in healthy participants under fasting condition. The main questions it aims to answer are:\n\n* \\[Question 1\\] Is there significant difference in the pharmacokinetic profile between the ferric carboxymaltose injection 750 mg iron\u002F15 mL provided by Sichuan Huiyu Pharmaceutical Co., Ltd. and the ferric carboxymaltose injection licensed by American Regent, Inc. (trade name: Injectafer®, strength:750 mg iron\u002F15 mL )?\n* \\[Question 2\\] Is it safe for healthy participants to take ferric carboxymaltose injection (750 mg iron\u002F15 mL \\[calculated by iron\\]) provided by Sichuan Huiyu Pharmaceutical Co., Ltd. under fasting condition? Participants will be randomly divided into two groups by stratified blocked randomization, with equal number of healthy participants in each group, to receive test product or reference product according to the protocol below.\n* Dosing on D1: Group T (Test product) Group R (Reference product)\n* PK blood sample collection\n* Safety evaluation",[30],"2026-05-18",{"date":305,"type":39},"2026-05-26",{"date":283,"type":24},{"date":308,"type":24},"2027-01-26",{"name":310,"class":203},"Sichuan Huiyu Pharmaceutical Co., Ltd",{"id":312,"slug":313,"hasResults":12,"nctId":314,"briefTitle":315,"officialTitle":316,"acronym":317,"eligibilityCriteria":318,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":319,"enrollmentInfo":320,"targetDuration":4,"studyType":25,"phases":322,"briefSummary":323,"conditions":324,"keywords":326,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":335,"lastUpdatePostDateStruct":336,"startDateStruct":338,"completionDateStruct":340,"leadSponsor":342,"locationsCount":47},"100635062","effects-of-a-robot-based-sensorimotor-upper-limb-rehabilitation-paradigm-in-chronic-stroke-100635062","NCT07547800","Effects of a Robot-based Sensorimotor Upper Limb Rehabilitation Paradigm in Chronic Stroke","Effects of a Robot-based Sensorimotor Upper Limb Rehabilitation Paradigm in Chronic Stroke: a Randomized Controlled Trial","RCT ROBUST","Inclusion Criteria stroke participants:\n\n1. Written informed consent must be obtained prior to any screening procedures;\n2. A first-ever unilateral, supra-tentorial stroke, as defined by WHO (rapidly developing clinical signs of focal (or global) disturbance of cerebral function, with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than vascular origin);\n3. ≥18 and ≤85 years old;\n4. Being a Dutch speaker;\n5. Being in the chronic phase after stroke, i.e. \\> 6 months post stroke;\n6. Motor impairment in the upper limb, defined as Fugl-Meyer score \\>22 out of 66 to demonstrate moderate to full upper limb motor function (patients scoring \\\u003C23 out of 66 will not be able to comply with the Kinarm protocol);\n7. Residual sensory upper limb impairment, defined as Tactile Discrimination Test (Area Under Curve) \\\u003C73.10%;\n8. Impaired functionality, defined as sensorimotor Action Research Arm Test score \\\u003C52 out of 57;\n9. Manageable spasticity for Kinarm tasks.\n\nInclusion Criteria healthy participants:\n\n1. Written informed consent must be obtained prior to any screening procedures;\n2. ≥18 and ≤85 years old;\n3. Being a Dutch or English speaker;\n4. No history of stroke or transient ischemic attack;\n5. No recent brain\u002Fhead injury;\n6. No major upper limb sensory or motor impairments.\n\nExclusion Criteria:\n\n1. Having musculoskeletal and\u002For other neurological disorders impacting care or prognosis;\n2. Having severe communication or cognitive deficits that interfere with the protocol;\n3. Having severe spasticity (cannot handle Kinarm robot);\n4. Any disorder, which in the investigator's opinion might jeopardise participant's safety or compliance with the CIP;\n5. Contraindications for robot-based therapy (e.g., uncontrolled epilepsy);\n6. Participation in another clinical investigation;\n7. Having any contraindications for fNIRS\\*：\n\n   * Uncontrolled head movements (e.g. tremor)\n   * Scalp lesion at optode sites (wound\u002Fincision\u002Finfection\u002Fhematoma)\n   * Decompressive craniectomy or large skull defect over target regions\n   * Persistent hair-optode coupling failure despite best practices, or non-removable obstructions preventing adequate coupling\n8. Having any contraindications for MRI\\*\\*:\n\n   * Pacemaker\n   * Implantable Cardioverter Defibrillator (ICD)\n   * Cochlear implant\n   * Internal Insulin-pump\n   * Deep brain stimulation\n   * Any other metal device in the body\n   * Claustrophobia\n   * Having a history of a neuropsychiatric or neurologic disorder before the diagnosis of stroke (e.g., depression, traumatic brain injury)\n   * Use of psychoactive medication before the diagnosis of stroke (e.g., anti-depressive medication)\n   * Misuse (or history of misuse) of drugs\u002Falcohol\n9. Currently undergoing a structured arm and\u002For hand training (e.g. engaging in playing a musical instrument)\\*\\*.\n\n   * Stroke patients and healthy participants showing these exclusion criteria will be included in the RCT protocol, but will not be measured with fNIRS.\n\n     * Stroke patients showing these exclusion criteria will be included in the RCT protocol, but will not be measured with MRI. Healthy adults showing these exclusion criteria will not be included in the study.","85 Years",{"count":321,"type":24},109,[27],"Sensorimotor function of the upper limb is commonly impaired after stroke, even in the chronic phase (\\>6 months post-stroke). Nevertheless, good sensorimotor function is needed for daily life functioning. Sensorimotor function can be divided into three components: exteroception, proprioception and sensory processing. It is important that those three components will each be addressed in the upper limb rehabilitation. Unfortunately, there is still no optimal therapy to address sensory processing. Therefore, the investigators developed an intensive sensorimotor robot-based rehabilitation paradigm (called ROBUST) with focus on sensory processing. As a first step, the investigators did a pilot study (S69003) including 10 persons with chronic stroke to investigate the potential effectiveness and feasibility of this novel rehabilitation. The median change score of motor, sensory and sensorimotor assessments was exceeding the minimal clinical important difference (MCID), and the total amount of therapy was feasible as well. The investigated protocols to measure potential changes in brain function (activity and connectivity) and structure accompanying the novel therapy appeared feasible as well. Based on this first pilot study, the investigators finalized the protocol for this RCT to investigate the effectiveness of the ROBUST intervention.",[325,30],"Stroke",[325,327,328,329,330,331,332,333,334],"Upper limb","Sensorimotor","Sensory processing","Robot-based therapy","MRI","fNIRS","Clinical outcomes","Kinematic outcomes","2026-05-06",{"date":337,"type":39},"2026-05-11",{"date":339,"type":24},"2026-04-17",{"date":341,"type":24},"2027-12-31",{"name":343,"class":46},"KU Leuven",{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":4,"eligibilityCriteria":350,"healthyVolunteers":12,"sex":351,"minAge":55,"maxAge":352,"enrollmentInfo":353,"targetDuration":4,"studyType":25,"phases":355,"briefSummary":356,"conditions":357,"keywords":358,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":363,"lastUpdatePostDateStruct":364,"startDateStruct":366,"completionDateStruct":367,"leadSponsor":369,"locationsCount":47},"100636572","digital-game-and-simulation-in-midwifery-education-100636572","NCT07567430","Digital Game and Simulation in Midwifery Education","The Effect Of Dıgıtal Game-Based Learnıng On Learnıng Motıvatıon And Attıtude In Preeclampsıa-Eclampsıa Educatıon In Mıdwıfery Students: Comparıson Wıth Sımulatıon And Tradıtıonal Educatıon","Inclusion Criteria:\n\n* Being an undergraduate midwifery student (4th year).\n* Giving written consent to the study.\n\nExclusion Criteria:\n\n* Having previously received advanced training or clinical assignment in preeclampsia\u002Feclampsia management.\n* Regularly using a similar digital game developed on the subject.\n* Health or cognitive limitations that prevent continuation of the research process (according to the student's statement).","FEMALE","25 Years",{"count":354,"type":24},120,[27],"Preeclampsia and eclampsia are among the leading causes of maternal death and morbidity, and are obstetric emergencies that lead to serious complications during pregnancy. Preeclampsia affects 2-8% of pregnancies worldwide; approximately 46,000 maternal deaths and approximately 500,000 fetal or neonatal deaths occur annually due to preeclampsia. This situation highlights the importance of well-equipped midwifery care, especially in terms of early diagnosis, accurate assessment, emergency intervention, and effective management.\n\nTraditional teaching methods alone are insufficient for midwifery students to develop clinical decision-making skills in life-threatening situations such as preeclampsia and eclampsia, and to translate theoretical knowledge into practice. Therefore, new teaching approaches that support active learning, interaction, and decision-making processes in education are needed.\n\nIn recent years, digital game-based learning has emerged as an innovative tool in health education with its potential to attract learners' attention, improve problem-solving skills, and increase their motivation. Especially for midwifery students, digital games facilitate experiential learning by providing a safe simulation environment in preparation for information overload and stressful clinical environments.\n\nHowever, the use of digital games in teaching complex clinical processes such as preeclampsia and eclampsia management has been researched to a limited extent. Scientifically examining the effects of such innovative methods on students' learning motivation, attitude, and active participation in the learning process in midwifery education will fill an important gap in the literature. In this context, evaluating digital game-based learning in preeclampsia-eclampsia management education by comparing it with simulation training and traditional teaching will make a significant contribution to both the midwifery education literature and the knowledge base regarding the use of technology in health education.",[30],[359,360,361,362],"digital game based learning","preeclampsia","eclampsia","midwifery education","2026-05-03",{"date":365,"type":39},"2026-05-05",{"date":286,"type":24},{"date":368,"type":24},"2027-01-30",{"name":370,"class":46},"Medipol University",{"id":372,"slug":373,"hasResults":12,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":231,"enrollmentInfo":379,"targetDuration":4,"studyType":25,"phases":380,"briefSummary":381,"conditions":382,"keywords":384,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":47},"100636095","effects-of-repetitive-transcranial-magnetic-stimulation-on-two-cerebellar-targets-100636095","NCT07561229","Effects of Repetitive Transcranial Magnetic Stimulation on Two Cerebellar Targets","Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Two Cerebellar Targets (Lobule VIII vs. CRUS I\u002FII)","StimCervelet","Inclusion Criteria:\n\n* Subject, male or female, aged between 18 and 60 years inclusive\n* Subject affiliated with or a beneficiary of a social security health insurance scheme\n* Subject has dated and signed the informed consent form prior to the start of any trial-related procedures\n* For women of childbearing potential, a negative urinary pregnancy test and the use of effective contraception throughout the duration of the study\n\nExclusion Criteria:\n\n* Subject with substance use disorders (as defined by the DSM-5)\n* Subject having taken benzodiazepines and related compounds (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product), cannabis (within the 2 months preceding inclusion), or hallucinogenic substances (within the period preceding inclusion, for a duration equivalent to 5 half-lives of the product)\n* Subject suffering from a neurological pathology or sequelae\n* Subject with Attention-Deficit\u002FHyperactivity Disorder (ADHD)\n* Subject with Borderline Personality Disorder\n* Subject presenting with disabling sensory impairments, specifically a visual acuity (corrected, if applicable) \\\u003C 0.8 (due to the use of visual materials; Freiburg Vision Test, Bach 1996; verified during an examination at the screening visit)\n* Subject deprived of liberty or under legal protection\n* Subject under guardianship or trusteeship\n* Pregnant or breastfeeding woman (verified by a urinary test at the screening visit)\n* Subject within an exclusion period defined by another clinical study or participating in a study likely to impact the results of the research\n* Subject presenting a contraindication for fMRI or rTMS: presence of non-removable ferromagnetic bodies, prostheses, pacemakers, implanted medication pumps, vascular clips or stents, heart valves or ventricular shunts, certain intracerebral clips, cochlear implants, history of seizures (epilepsy), or skin breach\u002Fpathology at the point of contact with the electrodes\n* Subject with a history of major neurological or psychiatric disease with current psychotropic medication (i.e., antipsychotics, benzodiazepines and related compounds, or hypnotics)",{"count":119,"type":24},[27],"The purpose of this study is to understand how different areas of the cerebellum (a part of the brain) control different functions and how they can be influenced by non-invasive brain stimulation.\n\nWhile researchers know that repetitive Transcranial Magnetic Stimulation (rTMS) can have positive effects on conditions like stroke and schizophrenia, they do not yet fully understand which specific stimulation settings work best or which exact parts of the cerebellum should be targeted for different symptoms.\n\nThis study compares the effects of stimulation on two specific regions:\n\n* Lobule VIII: Linked to movement and motor learning.\n* CRUS I\u002FII: Linked to attention, thinking (cognition), and predicting the timing of events.By comparing these areas, researchers hope to gain the information needed to develop better treatments for neurological and psychiatric disorders.\n\nThis is a randomized, double-blind study involving 40 healthy volunteers. Participants will be split into two groups:\n\n* Group 1: Receives \"exciting\" (activity-increasing) stimulation.\n* Group 2: Receives \"inhibiting\" (activity-decreasing) stimulation.\n\nEach participant will attend three different test sessions in a random order:\n\n* rTMS targeting Lobule VIII\n* rTMS targeting CRUS I\u002FII\n* Placebo (Sham) stimulation that looks and feels like the real thing but does not affect the brain.\n\nDuring each session, researchers will use brain imaging (fMRI) and computerized tasks to measure changes in brain connectivity and performance in motor and cognitive activities.\n\nThere is no direct medical benefit to the participants. However, the results will help scientists create better therapies for patients with brain-related health issues The risks are considered minimal. Common side effects of rTMS include temporary mild headaches or a clicking sound during stimulation. MRI scans can sometimes cause mild discomfort or a feeling of closed-in spaces (claustrophobia). Researchers have put safety measures in place, such as hearing protection and constant medical supervision during scans, to minimize these risks.",[383,30],"Healthy",[385,386,387,388,389,390,391,392,393],"Repetitive Transcranial Magnetic Stimulation (rTMS)","Cerebellum","Lobule VIII","Crus I\u002FII","Resting-state functional Magnetic Resonance Imaging (rs-fMRI)","Neuromodulation","Neuroplasticity","Excitatory vs. Inhibitory Stimulation","Neurotypical","2026-04-27",{"date":396,"type":39},"2026-05-01",{"date":398,"type":24},"2026-09-01",{"date":400,"type":24},"2030-01-02",{"name":402,"class":46},"University Hospital, Strasbourg, France",{"id":404,"slug":405,"hasResults":12,"nctId":406,"briefTitle":407,"officialTitle":408,"acronym":409,"eligibilityCriteria":410,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":411,"targetDuration":4,"studyType":25,"phases":413,"briefSummary":414,"conditions":415,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":417,"lastUpdatePostDateStruct":418,"startDateStruct":420,"completionDateStruct":422,"leadSponsor":424,"locationsCount":4},"100636324","foam-roller-compared-to-massage-on-reducing-calf-muscle-tone-in-healthy-subjects-100636324","NCT07564206","Foam Roller Compared to Massage on Reducing Calf Muscle Tone in Healthy Subjects","Effect of Foam Roller Compared to Massage on Reducing Calf Muscle Tone in Healthy Subject","FRTONE","Inclusion Criteria:\n\n1. Age: Participants aged between 18 and 45 years.\n2. Health Status: Healthy individuals with no prior musculoskeletal conditions in the lower limbs.\n3. Pain-Free: Participants should not have had pain in the gastrocnemius or Achilles tendon in the last 3 months.\n4. Willingness: Participants must provide informed consent and be available for the intervention and necessary evaluations.\n\nExclusion Criteria:\n\n1. Musculoskeletal Conditions: Individuals with any pathologies in the calf muscles (gastrocnemius, soleus) or Achilles tendon.\n2. Vascular or Neurological Issues: Participants with vascular diseases or neurological disorders that may interfere with the interventions or muscle response.\n3. Skin Conditions: Exclusion of participants with skin alterations, infections, or open wounds in the area of intervention.\n4. Pregnancy: Women who are pregnant.\n5. Sensitivity Issues: Participants with altered sensitivity in the lower limbs or any condition that may affect the response to the techniques.\n6. Non-Compliance: Individuals who do not provide informed consent or are not available for the required evaluations.",{"count":412,"type":24},20,[27],"Objective: This study aims to compare the effects of two techniques-foam rolling (FR) and therapeutic massage-on reducing the muscle tone in the calf muscles (gastrocnemius and soleus) of healthy individuals.\n\nMethods: A randomized, controlled crossover design was used with 40 healthy participants (aged 18-45). Participants were randomly assigned to either a foam roller or a therapeutic massage group. The interventions were applied to the dominant leg, and muscle tone was measured pre- and post-intervention using a MyotonPro device. The primary outcome was muscle tone (Hz), and secondary outcomes included muscle stiffness (N\u002Fm) and elasticity (D \\[log\\]).\n\nResults: The study will assess the effectiveness of each intervention on muscle tone, stiffness, and elasticity. It aims to determine whether foam rolling is as effective or superior to traditional massage in reducing calf muscle tone.\n\nConclusion: This research will contribute to understanding the efficacy of foam rolling as a self-administered technique for muscle tone reduction and its potential application in clinical and athletic settings",[416,30],"Muscle Tone","2026-04-26",{"date":419,"type":39},"2026-05-04",{"date":421,"type":24},"2026-05-15",{"date":423,"type":24},"2026-07-15",{"name":425,"class":46},"Universidad Europea de Madrid",{"id":427,"slug":428,"hasResults":12,"nctId":429,"briefTitle":430,"officialTitle":431,"acronym":4,"eligibilityCriteria":432,"healthyVolunteers":18,"sex":433,"minAge":55,"maxAge":4,"enrollmentInfo":434,"targetDuration":4,"studyType":25,"phases":436,"briefSummary":437,"conditions":438,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":440,"lastUpdatePostDateStruct":441,"startDateStruct":443,"completionDateStruct":445,"leadSponsor":447,"locationsCount":47},"100628981","early-phase-1-the-dosimetry-safety-and-diagnostic-efficacy-of-ga-fc516-in-healthy-subjects-and-patients-with-prostate-cancer-100628981","NCT07468708","The Dosimetry, Safety and Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer","Evaluation of Dosimetry, Safety, Biodistribution and Preliminary Diagnostic Efficacy of ⁶⁸Ga-FC516 in Healthy Subjects and Patients With Prostate Cancer","Inclusion Criteria:\n\n1. Voluntarily participate the clinical study; sign the informed consent form;\n2. Aged 18 years or older;\n3. Cohort A: Healthy subjects;\n4. Cohort B: Patients with prostate cancer confirmed by histopathological or cytological diagnosis;\n\nExclusion Criteria:\n\n1. Severe impairment of liver, kidney, or cardiac function;\n2. Severe obesity or other conditions that prevent or make PET\u002FCT scanning impossible;\n3. Hypersensitivity to any active or inactive components of the study drug;\n4. Other subjects deemed unsuitable for enrollment by the investigators.","MALE",{"count":435,"type":24},10,[184],"This goal of this study is to investigate the dosimetry, safety, biodistribution of ⁶⁸Ga-FC516. In this study, we will evaluate the safety, biodistribution and dosimetry of ⁶⁸Ga-FC516 in subjects and compared them with the results of ⁶⁸Ga-labeled prostate cancer-targeting tracer imaging to evaluate the dosimetric characteristics and diagnostic efficacy of ⁶⁸Ga-FC516.",[30,439],"Prostate Cancer","2026-04-24",{"date":442,"type":39},"2026-04-29",{"date":444,"type":39},"2026-03-09",{"date":446,"type":24},"2026-08",{"name":448,"class":203},"FindCure Biosciences (ZhongShan) Co., Ltd.",{"id":450,"slug":451,"hasResults":12,"nctId":452,"briefTitle":453,"officialTitle":453,"acronym":4,"eligibilityCriteria":454,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":455,"enrollmentInfo":456,"targetDuration":4,"studyType":25,"phases":458,"briefSummary":459,"conditions":460,"keywords":462,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":469,"lastUpdatePostDateStruct":470,"startDateStruct":472,"completionDateStruct":474,"leadSponsor":476,"locationsCount":47},"100630612","supraspinatus-tendon-acute-effects-after-two-exercise-exposures-a-crossover-randomized-trial-100630612","NCT07489937","Supraspinatus Tendon Acute Effects After Two Exercise Exposures: a Crossover Randomized Trial.","General inclusion criteria\n\n1. Between 18 and 45 years of age\n2. Able to perform physical activity with their shoulder (moderate arm exercise for 15 min, such as tennis or housework)\n\nGeneral exclusion criteria\n\n1. Shoulder fracture\n2. Frozen shoulder (\\>50% restriction in shoulder range of motion)\n3. Shoulder surgery\n4. Full rotator-cuff tears\n5. Bilateral shoulder pain\n6. Shoulder instability (history or positive apprehension test)\n7. Corticosteroid injection in the last 6 weeks\n8. Neurological diseases\n9. Cardiological diseases\n10. Systemic diseases (rheumatic diseases, autoimmune diseases)\n11. Uncontrolled diabetes\n12. Pregnancy\n\nGroup-specific inclusion criteria\n\n1. Shoulder pain group: report unilateral shoulder pain with an average shoulder pain score of≥ 3 in the last week.\n2. Control group: report no shoulder pain within 6 months.","45 Years",{"count":457,"type":24},24,[27],"The purpose of this study is to understand acute tendon changes after two exercise programs. We will invite individuals with and without shoulder pain to participate in this study. Every individual will participate in both exercise programs separated by up to 15 days. The researcher will evaluate the shoulder tendon using ultrasound before each exercise program and at 1 hour, 6 hours and 24 hours after each exercise program. The researcher will also evaluate self reported pain, pain sensitivity testing, and self reported questionnaires. We will compare the tendon changes after each exercise program, as well as between participants with and without shoulder pain.",[461,30],"Shoulder Pain",[463,464,465,466,161,467,468],"rotator cuff related shoulder pain","rotator cuff tendinopathy","shoulder pain","tendon thickness","subacromial pain","ultrasound","2026-04-21",{"date":471,"type":39},"2026-04-22",{"date":473,"type":39},"2026-04-20",{"date":475,"type":24},"2027-04-01",{"name":477,"class":46},"University of Florida",{"id":479,"slug":480,"hasResults":12,"nctId":481,"briefTitle":482,"officialTitle":483,"acronym":4,"eligibilityCriteria":484,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":56,"enrollmentInfo":485,"targetDuration":4,"studyType":25,"phases":486,"briefSummary":487,"conditions":488,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":47},"100635304","phase-1-study-to-evaluate-the-effect-of-food-and-a-proton-pump-inhibitor-on-the-pharmacokinetics-of-vrn101099-in-healthy-adult-participants-100635304","NCT07550946","Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants","A Phase 1, Open-label, Randomized, 3-Period, 2-Sequence, Crossover Study to Evaluate the Effect of Food and a Proton Pump Inhibitor on the Pharmacokinetics of VRN101099 in Healthy Adult Participants","Inclusion Criteria:\n\n1. Male or female aged between 18 and 65 years of age (inclusive at the time of informed consent).\n2. In good general health, with no significant medical history, and have no clinically significant abnormalities on physical examination at Screening and\u002For before the first administration of IP (at the discretion of the PI or designee).\n3. BMI between ≥ 18.0 and ≤ 32.0 kg\u002Fm2 and weight ≥ 50 kg at Screening.\n4. Clinical laboratory values within normal range as specified by the testing laboratory, unless deemed not clinically significant by the PI or designee. Note: Repeat testing at Screening is acceptable for out-of-range values at the discretion of the Investigator.\n5. Female participants must be either not of childbearing potential or if they are a woman of childbearing potential and are engaged in heterosexual intercourse, they must agree to use an acceptable, highly effective contraception method in conjunction with a condom for the male partner from Screening until 100 days after the last dose of IP (ie, 90 days plus 5 half-lives of the IP).\n6. Male participants must not be of childbearing potential, or if they are engaged in sexual relations with WOCBP, they must agree to use a condom in conjunction with an acceptable, highly effective contraception method for the female partner from Screening until 100 days after the last dose of the IP.\n7. Males must not donate sperm and females must not donate ova from the first dose of IP until at least 100 days after the last dose of IP (ie, 90 days plus 5 half-lives of the IP).\n8. Able and willing to attend the necessary visits to the CRU.\n9. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.\n\nExclusion Criteria:\n\n1. Underlying physical or psychological medical condition that, in the opinion of the PI or designee, would make it unlikely for the participant to comply with the protocol or complete the study per protocol. This includes but may not be limited to: medical histories (eg, hepatic\u002Fbiliary, renal, cardiovascular, endocrine, respiratory, digestive, haematologic, oncologic \\[except for non-melanoma skin cancer, excised more than 2 years ago and cervical intraepithelial neoplasia that has been successfully cured more than 5 years prior to the first administration of IP\\], central nervous system, psychiatric, musculoskeletal) or past medical\u002Fsurgical histories that may affect drug absorption, distribution, metabolism, or excretion (excluding simple appendectomy or herniorrhaphy).\n2. Participants with known or suspected conditions or significant gastrointestinal disorders that may interfere with drug absorption (eg, inflammatory bowel disease, chronic diarhoea, malabsorption syndromes, or prior gastrointestinal surgery affecting absorption).\n3. History of severe allergic or anaphylactic reactions, or sensitivity to the IP or its constituents.\n4. History of hypersensitivity and\u002For intolerance to PPIs.\n5. History of infections requiring parenteral antibiotics within 6 months prior to the first administration of IP.\n6. Blood donations of ≥ 400 mL or significant blood loss within 60 days prior to the first administration of investigational product (IP), plasma donation within 7 days prior to the first administration of IP, or platelet donation within 30 days prior to the first administration of IP. Participants must also agree not to donate blood, plasma, or platelets during the study and for at least 30 days after the last dose of IP.\n7. Abnormal findings on 12-lead (triplicate) ECG at Screening that are considered by the PI or designee to be clinically significant; or has a QTcF (Fridericia's formula) interval at Screening of \\> 450 msec for males or \\> 470 msec for females based on the average of the 3 readings. Repeat testing at Screening is acceptable for abnormal values at the discretion of the Investigator (once per parameter).\n8. Abnormal vital sign findings at Screening that are considered clinically significant by the Principal Investigator (PI) or designee, including systolic blood pressure \\>140 mmHg or \\\u003C 90 mmHg, diastolic blood pressure \\> 90 mmHg or \\\u003C 50 mmHg, or a history of symptomatic hypotension. If a screening value falls outside these limits, repeat measurement is permitted at the discretion of the Investigator, with one repeat assessment allowed per parameter. Eligibility should be based on the repeat value.\n9. Active liver disease, or AST and\u002For ALT \\> 1.5 × upper limit of normal at Screening. Note: Repeat testing at Screening is acceptable for out-of-range values at the discretion of the Investigator.\n10. Estimated glomerular filtration rate (eGFR) of ≤ 80 mL\u002Fmin\u002F 1.73 m2 based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 formula.\n11. Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), or human immunodeficiency virus (HIV) antibody at Screening.\n12. Use of (or anticipated use of) any prescription drugs (other than hormonal contraception; oral contraceptive pills, long-acting implantable hormones, injectable hormones, a vaginal ring, or an intrauterine device), within 14 days prior to the first administration of the IP; or use of any over the counter medication, herbal remedies, supplements, or vitamins within 7 days prior to the first administration of IP and during course of study. Note: Simple analgesia (eg, paracetamol) may be permitted at the discretion of the PI, provided they are used within the recommended maximum daily doses as specified in the package insert.\n13. Use of any drugs, herbal supplements, or foods that are known to be strong or moderate inhibitors\u002Finducers of CYP3A4 (eg, carbamazepine, rifampin, St. John's wort, ketoconazole, ginkgo biloba, grapefruit, grapefruit juice) from within 30 days prior to the first administration of IP until the end of the study.\n14. Use of PPIs, histamine (H)2 blockers, potassium-competitive acid blockers, or locally-acting antacids within 8 weeks before the first dose of IP, or requiring these medications during the study (except for the planned use of rabeprazole specified in the protocol)\n15. Vaccination with a live vaccine within 4 weeks prior to the first administration of IP (and up until 14 days after the last dose of the IP).\n16. Use of any IP or investigational medical device within 30 days prior to the first administration of IP, or 5 half lives of the product (whichever is the longest), and during the course of the study.\n17. Positive toxicology screening panel (urine test including qualitative identification of amphetamines, methamphetamines, methadone, barbiturates, benzodiazepines, cocaine, opiates, methylenedioxymethamphetamine, phencyclidine, tetrahydrocannabinol, and tricyclic antidepressants), or alcohol breath test at Screening. Note: A single repeat test in the event of a false positive is permitted for the drug of abuse urine test at the discretion of the Investigator.\n18. History of regular alcohol consumption defined as \\> 14 standard drinks per week or \\> 3 standard drinks on any single day (where 1 standard drink = 10 g of alcohol) within 3 months prior to Screening.\n19. Unwilling or unable to abstain from the consumption of alcohol and caffeine containing food or drinks beginning 72 hours prior to the first administration of IP and until the end of the study.\n20. Unwilling to abstain from cigarettes or nicotine-containing products (eg, cigars, vapes, nicotine patches) for at least 7 days prior to first IP administration through to the end of the study, or is considered to be dependent on nicotine at the discretion of the PI. Note: Participants that are considered light or social smokers (defined as ≤ 5 cigarettes per week) will be considered eligible for entry into the study but must also adhere to these restrictions.\n21. Unwilling to refrain from strenuous exercise (including weightlifting) from 48 hours prior to each admission (on Day -1, Day 11, and Day 28), during the inpatient stays, and for 48 hours prior to any outpatient visit (including the EOS visit).\n22. Unable or unwilling to consume a high-fat meal.\n23. Pregnant or lactating.\n24. Poor peripheral venous access.\n25. Anything that the PI considers that would jeopardize the safety of the participant, prevent complete participation in the study, or compromise interpretation of study data.",{"count":457,"type":24},[216],"This Clinical trial is being done to understand how food and a common stomach-acid reducing medicine (called a proton pump inhibitor-PPI) affect how the body absorbs a new drug, VRN101099, in healthy adults.\n\nResearchers will measure how much of the drug gets into the bloodstream and how fast it gets there in each situation.\n\nThis will help identify the most effective way for future patients to use VRN101099 in the treatment of solid tumors and cancers.\n\nThe main questions it aims to answer is:\n\n1. Does food or a PPI change how the body absorbs a single dose of VRN101099?\n2. Is a single dose of VRN101099 safe and well tolerated when taken with or without food or a PPI?\n3. How is VRN101099 removed through urine when taken with or without food or a PPI?",[30],"2026-04-19",{"date":440,"type":39},{"date":264,"type":24},{"date":493,"type":24},"2026-09-30",{"name":495,"class":203},"Voronoi, Inc",{"id":497,"slug":498,"hasResults":12,"nctId":499,"briefTitle":500,"officialTitle":501,"acronym":4,"eligibilityCriteria":502,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":503,"targetDuration":4,"studyType":25,"phases":505,"briefSummary":506,"conditions":507,"keywords":509,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":517,"lastUpdatePostDateStruct":518,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":47},"100635044","recovery-after-fatigue-in-young-athletes-comparison-between-tecar-therapy-and-cycle-ergometer-100635044","NCT07547566","Recovery After Fatigue in Young Athletes: Comparison Between TECAR Therapy and Cycle Ergometer\"","Immediate and Short-term Effects of TECAR Therapy and Cycle Ergometer on Recovery After Fatigue in Young Athletes: a Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Engaging in regular physical activity\n* Experience with sports involving jumping or plyometric exercises\n\nExclusion Criteria:\n\n* Performed intense physical exercise within 24 hours before the study\n* Planned to perform intense physical exercise within 24 hours after the study\n* Presence of muscle soreness at the beginning of the study\n* Musculoskeletal injury in the previous 6 months",{"count":504,"type":24},48,[27],"The goal of this clinical trial is to compare two recovery methods after fatigue in young athletes. It aims to find out if tecar therapy (TECAR) or cycle ergometer exercise can improve recovery after intense physical activity and help athletes return to their normal performance more quickly.\n\nThe main questions it aims to answer are:\n\nDoes TECAR or cycle ergometer improve physical performance after fatigue?\n\nDo these methods reduce muscle pain and soreness after fatigue?\n\nResearchers will compare TECAR with active recovery using a cycle ergometer to see which method is more effective.\n\nParticipants will:\n\nPerform a series of jumps to induce fatigue\n\nBe randomly assigned to one of the recovery methods\n\nComplete physical tests before and after fatigue\n\nUndergo simple measurements of muscle condition and pain\n\nReport their level of effort and muscle soreness",[508,30],"Muscle Fatigue",[90,508,510,511,512,513,514,515,516],"Athletes","Recovery of Function","Countermovement jump","Pressure pain threshold","Muscle soreness","Muscle mechanical properties","Diathermy","2026-04-16",{"date":519,"type":39},"2026-04-23",{"date":521,"type":24},"2026-04",{"date":523,"type":24},"2026-11",{"name":525,"class":46},"Maimónides Biomedical Research Institute of Córdoba",{"id":527,"slug":528,"hasResults":12,"nctId":529,"briefTitle":530,"officialTitle":531,"acronym":4,"eligibilityCriteria":532,"healthyVolunteers":18,"sex":19,"minAge":116,"maxAge":533,"enrollmentInfo":534,"targetDuration":4,"studyType":25,"phases":535,"briefSummary":536,"conditions":537,"keywords":538,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":544,"lastUpdatePostDateStruct":545,"startDateStruct":546,"completionDateStruct":547,"leadSponsor":549,"locationsCount":47},"100634500","phase-1-pharmacokinetics-and-safety-of-gh001-delivered-via-a-gh001-aerosol-delivery-system-in-healthy-subjects-100634500","NCT07540494","Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects","An Open-label Phase 1 Trial to Determine the Pharmacokinetics, Pharmacodynamics and Safety of GH001 Administered Via a GH001 Aerosol Delivery System in Healthy Subjects","Inclusion Criteria:\n\n* Body mass index (BMI) in the range of 18.5 to 35 kg\u002Fm2 (inclusive) at screening.\n* Good mental health in the opinion of the investigator.\n* Normal spirometry (FEV1 of \\>80% of predicted and FVC of \\>80% of predicted value) at screening.\n\nExclusion Criteria:\n\n* Has known allergies or hypersensitivity or any other contraindication to mebufotenin, bufotenin, melatonin or triptans.\n* Has received any investigational medication, including investigational vaccines, in the 90 days prior to baseline or is in the follow-up period of another clinical trial at the time of screening for this trial.\n* Has a current or past clinically significant condition, which renders the subject unsuitable for the trial according to the investigator's judgement.","64 Years",{"count":214,"type":24},[216],"The primary objectives of this trial are to determine the pharmacokinetic (PK) profile and the safety and tolerability of GH001 delivered via a proprietary aerosol delivery device in healthy subjects after single-dose administration.",[30],[539,540,541,542,136,543],"Mebufotenin","5-MeO-DMT","5-methoxy-N,N-dimethyltryptamine","GH001","Pharmacokinetics","2026-04-14",{"date":473,"type":39},{"date":521,"type":24},{"date":548,"type":24},"2026-05",{"name":550,"class":203},"GH Research Ireland Limited",{"id":552,"slug":553,"hasResults":12,"nctId":554,"briefTitle":555,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":18,"sex":19,"minAge":455,"maxAge":56,"enrollmentInfo":558,"targetDuration":4,"studyType":25,"phases":560,"briefSummary":561,"conditions":562,"keywords":563,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":572,"locationsCount":47},"100625919","nicotinamide-adenine-dinucleotide-responses-to-a-nutritional-supplement-100625919","NCT07428889","Nicotinamide Adenine Dinucleotide Responses to a Nutritional Supplement","A Randomized, Controlled, Pilot Trial to Assess the Effects of a Proprietary Nutritional Supplement on Nicotinamide Adenine Dinucleotide (NAD+) Responses in Healthy Adults","Inclusion Criteria:\n\n1. Males and females, ≥45 to ≤65 years of age\n2. BMI ≥18.5 and \\\u003C30.0 kg\u002Fm2\n3. Ambulatory and currently free of injury or other physical impairment that hinders mobility.\n4. Willing to use personal smart phone with operating system (Android version 12.0 or newer; iOS version 16 or newer).\n5. Willingness to maintain current skin care regimen and avoid any skin-related medical procedures.\n6. Willing to adhere to all study procedures, including lifestyle considerations and sign forms providing informed consent to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.\n\nExclusion Criteria:\n\n1. Is currently following, or planning to be on, a weight loss regimen.\n2. Weight loss or gain \\>4.5 kg.\n3. History of gastrointestinal surgery for weight reducing purposes.\n4. History of an eating disorder (e.g., anorexia nervosa or bulimia nervosa, binge eating) at the discretion of the Clinical Investigator.\n5. History of neurologic disorder that could produce cognitive deterioration.\n6. History of bouts of delirium, confusion, repeated minor head injury or a single injury.\n7. History of unconventional sleep patterns or a diagnosed sleep disorder.\n8. History of any infective or inflammatory brain disease.\n9. Use of tobacco\u002Fnicotine products.\n10. Use of hemp\u002Fmarijuana products.\n11. Unstable use of any prescription medication.\n12. Unstable use (initiation or change in dose) of hormonal contraceptives or therapy.\n13. Use of any dietary supplements (orally or infused), other than a conventional once daily multi-vitamin.\n14. Use of medication(s) or dietary supplement(s) known to affect absorption.\n15. Recent history of or strong potential for alcohol or substance abuse.\n16. Exposed to any non-registered drug product.\n17. A score of \\\u003C7 on the Vein Access Scale Assessment.\n18. History or presence, on the basis of the medical history or screening labs, of clinically important cardiac, renal, hepatic, endocrine (including diabetes mellitus), pulmonary, gastrointestinal, biliary, pancreatic, or neurological disorders.\n19. Uncontrolled hypertension.\n20. Known allergy to any ingredients contained in the study product.\n21. Any signs or symptoms of active infection of clinical relevance.\n22. History or presence of cancer in the prior 2 years, except for non-melanoma skin cancer.\n23. History of any major trauma or major surgical event.\n24. Female who is pregnant, planning to be pregnant during the study period, lactating, or is of childbearing potential with unstable use of sex hormones for contraception.\n25. An employee or representative who has a financial interest in Sponsor organization.",{"count":559,"type":24},34,[27],"The objective of this study is to evaluate nicotinamide adenine dinucleotide (NAD+) in response to a proprietary nutritional supplement in generally healthy adults, compared to placebo.",[30],[564,565],"NAD+ metabolism","Markers of health","2026-04-09",{"date":568,"type":39},"2026-04-13",{"date":570,"type":39},"2026-02-17",{"date":41,"type":24},{"name":573,"class":203},"Shaklee Corporation",{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":580,"eligibilityCriteria":581,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":582,"enrollmentInfo":583,"targetDuration":4,"studyType":25,"phases":584,"briefSummary":585,"conditions":586,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":588,"startDateStruct":589,"completionDateStruct":591,"leadSponsor":593,"locationsCount":47},"100631379","phase-1-phase-1-trial-to-evaluate-150-mg-subcutaneous-cit-013-100631379","NCT07499908","Phase 1 Trial to Evaluate 150 mg Subcutaneous CIT-013","A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Trial to Evaluate 150 mg Subcutaneous CIT-013 Administration in Healthy Adult Volunteers","Citysky","Inclusion Criteria:\n\nHealthy men or women, 18 to 75 years of age (inclusive) at screening.\n\nExclusion Criteria:\n\nEvidence of any active or chronic disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the trial, or that would pose an unacceptable risk to the participant in the opinion of the Investigator.","75 Years",{"count":435,"type":24},[216],"This is a phase 1, double-blind, randomized, placebo-controlled, single center, repeat-dose trial for the assessment of safety, tolerability, bioavailability and pharmacokinetic profiles of 150 mg CIT-013 in healthy adult volunteers",[30],"2026-04-08",{"date":568,"type":39},{"date":590,"type":24},"2026-05-31",{"date":592,"type":24},"2026-10-31",{"name":594,"class":203},"Citryll BV",{"id":596,"slug":597,"hasResults":12,"nctId":598,"briefTitle":599,"officialTitle":600,"acronym":601,"eligibilityCriteria":602,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":4,"enrollmentInfo":603,"targetDuration":4,"studyType":25,"phases":604,"briefSummary":605,"conditions":606,"keywords":607,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":587,"lastUpdatePostDateStruct":610,"startDateStruct":611,"completionDateStruct":612,"leadSponsor":613,"locationsCount":47},"100632763","cerebrospinal-fluid-kinetics-of-urolithin-a-100632763","NCT07517913","Cerebrospinal Fluid Kinetics of Urolithin A","Cerebrospinal Fluid Kinetics of Urolithin A in Humans","neURO","Inclusion Criteria:\n\n* 1\\. Healthy male and female participants aged between 18 and 45 years (both inclusive);\n* 2\\. Non-smoker subject or smoker of not more than 5 cigarettes a day;\n* 3\\. Body Mass Index (BMI) between 18.50-30.00 kg\u002Fm2 inclusive;\n* 4\\. Trial participants in normal health as determined by personal medical history, clinical examination including vital signs, and clinically acceptable results of laboratory examinations (including serological tests), individual values out of the normal range can be accepted if judged clinically non relevant by the Investigator;\n* 5\\. Normal electrocardiogram (ECG) recording on a 12-lead ECG and\u002For chest X-ray (PA view) significant at the screening visit or considered not clinically significant (NCS) by investigators;\n* 6\\. A negative alcohol breath test result at housing;\n* 7\\. Trial participant able to communicate effectively, provide voluntary written informed consent and available for the entire study duration;\n* 8\\. Trial participants willing to adhere to the protocol requirements as evidenced by written informed consent approved by the ethics committee;\n* 9\\. Ability to fast for at least 14.00 hours and consume standard meals;\n* 10\\. Accept to refrain consuming certain foods and supplements at least two weeks before inclusion;\n* 11\\. Female participants must have a negative urine pregnancy test prior to housing;\n* 12\\. Trial participants that can provide adequate evidence of their identity;\n* 13\\. The participants agree to refrain from consuming dietary supplements that could potentially impact either muscle or mitochondrial function or contain Urolithin A, such as resveratrol, pomegranate and ellagitannins, nicotinamide riboside, whey protein, leucine, iso-leucine, l-carnitine, creatinine, coenzyme Q10, vitamin A, niacin, folic acids, vitamin C, vitamin E and probiotic foods and supplements, during the 2 weeks before inclusion and throughout the study;\n* 14\\. Females of childbearing potential agree to use appropriate contraceptive measures like non-hormonal intrauterine devices, barrier methods, and spermicidal agents during the study and 07 days after completion of the study;\n* 15\\. Male agreeing to use appropriate contraceptive measures like the Double Barrier method (Condom), and should not donate sperm, etc. during the study and 07 days after completion of the study.\n\nExclusion Criteria:\n\n* 1\\. Known hypersensitivity to Urolithin A or related product or any component of intervention, presence or history of drug hypersensitivity, allergic disease or lactose intolerance;\n* 2\\. Any history or presence of clinically significant medical condition, such as, but not limited to, cardiovascular, pulmonary, gastro-intestinal, hepatic, renal, metabolic, hematological, neurologic, psychiatric, systemic or infectious disease, thyroid disease, adrenal dysfunction, or organic intracranial lesion;\n* 3\\. Any treatment which could bring about induction or inhibition of the hepatic microsomal enzyme system within one month of starting the study;\n* 4\\. History or presence of alcoholism or drug abuse;\n* 5\\. History or presence of gastric and\u002For duodenal ulceration;\n* 6\\. History or presence of cancer;\n* 7\\. Difficulty with donating blood;\n* 8\\. Use of any prescribed medication (including herbal remedies) during the two weeks before the start of the study or OTC medicinal products (including herbal remedies) during the week before study initiation and throughout the study;\n* 9\\. Use of medications such as benzodiazepines, anticonvulsants, or barbiturates for one month before the start of the study and throughout the study;\n* 10\\. Trial participant consumed tobacco\u002Ftobacco-containing products, pan or pan masala, gutkha, and masala (containing beetle nut and tobacco) for at least 48.00 hours before initiation of the study and throughout the study;\n* 11\\. Trial participant consumed caffeine and\u002For xanthine-containing foods or beverages (i.e., coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.) and grapefruit juice and poppy-containing foods for at least 48.00 hours before initiation of the study and throughout the study;\n* 12\\. Major illness during the 90 days before screening;\n* 13\\. Participation in a drug research study within 90 days of screening;\n* 14\\. Positive screening test result for any one or more of the following: HIV, Hepatitis B, Hepatitis C, and VDRL;\n* 15\\. History or presence of easy bruising or bleeding;\n* 16\\. Abnormal diet pattern for whatever reason (e.g., low sodium, fasting, and high protein diets) during the four weeks preceding the study;\n* 17\\. Females of childbearing potential with any one of the following reported and documented on the medical history:i. Postmenopausal with spontaneous amenorrhea for at least one year, orii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, oriii. Total hysterectomy and an absence of bleeding for at least 3 months;iv. Female volunteers who have used implanted or injected hormonal contraceptives anytime during the 6 months prior to study or used hormonal contraceptives within 07 days before dosing;\n* 18\\. Pregnant women and nursing mothers;\n* 19\\. Male and females of childbearing potential unwilling to employ appropriate and reliable method of contraception like non-hormonal intrauterine devices, barrier methods, and spermicidal agents, Double Barrier method (Condom) during the study till 07 days after the completion of the study;\n* 20\\. Male volunteers willing to donate sperm during the study till 07 days after the completion of the study.\n* 21\\. Allergy to peanuts, nuts, pea, or gum guar.",{"count":119,"type":24},[27],"The purpose of this study is to determine the impact of Mitopure® consumption on urolithin A (UA) kinetics in cerebral spinal fluid (CSF).",[30],[608,609],"Mitopure","Urolithin A",{"date":568,"type":39},{"date":396,"type":24},{"date":475,"type":24},{"name":614,"class":203},"Amazentis SA",{"id":616,"slug":617,"hasResults":12,"nctId":618,"briefTitle":619,"officialTitle":619,"acronym":620,"eligibilityCriteria":621,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":56,"enrollmentInfo":622,"targetDuration":4,"studyType":87,"phases":4,"briefSummary":624,"conditions":625,"keywords":4,"overallStatus":69,"whyStopped":4,"lastUpdateSubmitDate":627,"lastUpdatePostDateStruct":628,"startDateStruct":630,"completionDateStruct":632,"leadSponsor":633,"locationsCount":47},"100622851","investigating-specific-gait-patterns-in-individuals-living-with-multiple-sclerosis-100622851","NCT07388992","Investigating Specific Gait Patterns in Individuals Living With Multiple Sclerosis","GAIT-MS","Inclusion Criteria:\n\nFor people living with multiple sclerosis (pwMS):\n\n1. Age at inclusion between =18 and =65 years old\n2. Signed informed consent and ability to comply with study and follow-up.\n3. Confirmed MS diagnosis according to McDonald criteria (2017)\n4. Expanded Disability Status Scale EDSS = 6\n5. Stable treatment for 2 months before inclusion (for both disease modifying and symptomatic therapies)\n6. Ability and willingness to participate in and comply with all study procedures defined in the protocol\n7. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category\n\nFor Healthy volunteers :\n\n1. Age at inclusion between =18 and =65 years old\n2. Signed informed consent and ability to comply with study and follow-up.\n3. Ability and willingness to participate in and comply with all study procedures defined in the protocol\n4. Subject will be eligible for enrollment in this study only if either affiliated to, or a beneficiary of a social security category\n\nExclusion Criteria:\n\nFor pwMS:\n\n1. Participants with a relapse within the past 3 months before the inclusion\n2. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator\n3. Past or present pathology other than MS or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator\n4. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.\n\nFor healthy volunteers (HV):\n\n1. Participants with significant cognitive disorders, limiting the understanding of the exercises to be performed or presence of apparent communication difficulties hindering the correct collection of data, as assessed by the investigator\n2. Past or present pathology or surgery or trauma impacting gait, ambulatory function or upper limb function, as assessed by the investigator\n3. Vulnerable adults: individuals subject to a legal protection measure (guardianship, limited guardianship, or judicial protection) or unable to express their consent.",{"count":623,"type":24},30,"The study aims to investigate specific ambulation patterns characteristic of the quality of gait in people with MS (pwMS)",[626,30],"Multiple Sclerosis","2026-03-20",{"date":629,"type":39},"2026-03-23",{"date":631,"type":39},"2026-03-16",{"date":41,"type":24},{"name":634,"class":203},"SYSNAV",{"id":636,"slug":637,"hasResults":12,"nctId":638,"briefTitle":639,"officialTitle":640,"acronym":4,"eligibilityCriteria":641,"healthyVolunteers":18,"sex":19,"minAge":55,"maxAge":56,"enrollmentInfo":642,"targetDuration":4,"studyType":25,"phases":643,"briefSummary":644,"conditions":645,"keywords":646,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":631,"lastUpdatePostDateStruct":650,"startDateStruct":652,"completionDateStruct":654,"leadSponsor":655,"locationsCount":47},"100625849","sex-differences-in-exercise-induced-hypoalgesia-100625849","NCT07427979","Sex Differences in Exercise-Induced Hypoalgesia","Sex Differences in Exercise-Induced Hypoalgesia Following Aerobic Exercise Using a Lower-Limb Cycle Ergometer: A Quasi-Experimental Study","Inclusion Criteria:\n\n* Healthy male and female adults\n* Age between 18 and 65 years\n* Able to perform moderate-to-vigorous aerobic exercise\n* Able to understand study procedures\n* Cleared for exercise participation using the Physical Activity Readiness Questionnaire (PAR-Q).\n\nExclusion Criteria:\n\n* Cardiovascular, respiratory, neurological, or metabolic diseases contraindicating exercise\n* Current musculoskeletal pain or injury\n* Analgesic medication use within 24 hours prior to testing\n* Vigorous exercise within 24 hours prior to testing\n* Any contraindication to aerobic exercise",{"count":623,"type":24},[27],"Exercise-induced hypoalgesia (EIH) refers to the reduction in pain sensitivity following acute exercise. Although aerobic exercise has been shown to induce hypoalgesia in healthy individuals, it remains unclear whether the magnitude of this response differs between men and women.\n\nThis quasi-experimental study aims to evaluate sex differences in pressure pain thresholds following a standardized aerobic exercise protocol using a lower-limb cycle ergometer. Pressure pain thresholds will be assessed before exercise, immediately after exercise, and 30 minutes after exercise in healthy adults aged 18 to 65 years.\n\nThe findings of this study may contribute to improving individualized exercise prescription strategies based on sex differences in pain modulation.",[30],[647,648,649],"Exercise-Induced Hypoalgesia","Sex differences","Aerobic exercise",{"date":651,"type":39},"2026-03-18",{"date":653,"type":24},"2026-03-15",{"date":423,"type":24},{"name":656,"class":46},"Centro Universitario La Salle"]